Agilent Technologies stock holds steady as business context matters
Published on 07/12/2026 at 02:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Agilent Technologies (ISIN US00846U1016) is a Nasdaq-listed life sciences and diagnostics company whose business spans analytical instruments, diagnostics, and laboratory workflow tools.
Business profile
Agilent Technologies, Inc. operates across three main areas: life sciences and applied markets, diagnostics and genomics, and Agilent CrossLab. That structure gives the company exposure to research labs, biopharma, and clinical testing demand rather than a single end market.
Market context
For investors, that mix matters because Agilent's revenue base is tied to recurring consumables and service activity as well as instrument sales. The company trades on Nasdaq in U.S. dollars, which keeps it firmly in the U.S. large-cap market conversation.
More on Agilent Technologies stock
Agilent's product mix links lab spending, diagnostics, and recurring service revenue. That makes the company useful to follow as a read on research and testing budgets.
Agilent's core products
Representative products include liquid chromatography systems, mass spectrometry platforms, and diagnostics assays used in laboratories and testing facilities. Those offerings anchor the company in instrument replacement cycles and ongoing consumables demand.
Stock level
Agilent Technologies stock is listed on Nasdaq under A, with the company positioned as a U.S. life sciences and diagnostics name.
Fact box
- Company: Agilent Technologies, Inc.
- ISIN: US00846U1016
- Ticker: A
- Exchange: Nasdaq
- Sector / Industry: Health Care, Life Sciences Tools & Services
- Index membership: S&P 500
- Next earnings date: not yet officially scheduled
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
